首頁 > 市場調查報告書 > 醫療設備

傷口護理

市場調查報告書

商品編碼

1804262

止血劑的全球市場:各類型，各製劑，各用途，各終端用戶，各流通管道，各地區 - 市場規模，產業動態，機會分析，預測(2025年～2033年)

Global Hemostats Market: Type, Formulation, Application, End Users, Distribution Channel, Region-Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033

出版日期: 2025年05月19日 | 出版商:

Astute Analytica | 英文 227 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

止血劑市場與全球外科手術的步伐密切相關，反映了越來越多的外科手術對有效止血的需求日益增長。 2024 年，該市場規模約為 28.8413 億美元，預計將穩定成長，到 2033 年將達到 48.3968 億美元，2025 年至 2033 年的複合年增長率為 5.92%。推動這一增長的主要因素之一是微創手術技術（例如腹腔鏡手術和機器人手術）的日益普及。

按地區劃分，受益於完善的醫療基礎設施和較高的手術量，北美繼續在止血劑消費市場佔主導地位。然而，亞太地區正在迅速崛起，這得益於政府資助的創傷網絡的大量投資以及腹腔鏡手術的激增，尤其是在中國和印度等人口大國。這種成長預示著市場格局的轉變，並成為止血劑製造商的關鍵成長引擎，這些製造商正尋求利用亞太地區外科手術數量的成長和醫療保健覆蓋面的擴大。

值得關注的市場發展

止血劑市場由強生、百特國際、輝瑞公司、貝朗公司和碧迪公司 (BD) 等主要參與者推動。這些產業領導者擁有強大的全球影響力，並始終致力於透過積極的研發、策略合作夥伴關係和持續的產品創新來提升其市場地位。

百特國際的內部應用止血實驗室體現了這種創新驅動的方法，該實驗室擁有一支由 50 名科學家組成的團隊，致力於開發下一代止血解決方案。光是在2023年，該研究所就提交了42個專利家族，重點在於剪切稀化明膠和冷凍保護性凝血酶複合物等先進材料。這些創新旨在提高止血劑的有效性和多功能性，並滿足現代外科手術的精細需求。

同時，BD正在透過收購策略性地擴展其產品組合，例如以2.14億美元收購Tissuemed。此次收購使BD能夠使用Tissuemed的超薄聚乙二醇貼片技術，從而拓寬其產品範圍，並為市場提供更專業、更有效的止血選擇。此舉顯示BD致力於透過創新產品的定向投資來鞏固其市場地位。

關鍵成長動力

微創手術（MIS）數量的快速成長是推動止血劑市場擴張的最強因素。根據國際微創外科學會 (International Society for Micro-Invasive Surgery) 的數據，預計到 2024 年，全球將實施約 1.08 億例腹腔鏡、機器人和內視鏡手術。與 2022 年相比，這一數字將增加約 1,100 萬例，這表明微創外科技術 (MIS) 正在加速應用於各種外科手術。

目前，約三分之一的微創手術會使用止血鉗，預計光在 2024 年就將使用約 3,600 萬組止血鉗。這種廣泛的應用凸顯了止血鉗在實現安全且高效的 MIS 手術中發揮的關鍵作用。微創技術的持續發展預計將維持對止血鉗產品的強勁需求，進一步推動市場創新和成長。

新的機會趨勢

膠原蛋白-殼聚醣混合止血鉗正引起越來越多的科學關注，這一趨勢正在顯著改變止血鉗市場的競爭態勢。這些混合製劑將膠原蛋白的有益特性與殼聚醣的獨特性能相結合，從而提高了止血性能和組織相容性。 2023年1月至2024年3月，歐洲醫療器材資料庫 (EUDAMED) 記錄了11項新的膠原蛋白-殼聚醣混合產品CE標誌批准，而同期氧化纖維素基止血劑僅有3項批准。

本報告分析了全球止血劑市場，提供了每個細分市場的市場規模和預測、市場動態和趨勢以及公司概況。

產業價值鏈分析
- 材料供應商
- 廠商
- 批發商
- 終端用戶
產業預測
- 天然來歷的局部·外用止血生物材料
- 合成來歷的局部·外用止血生物材料
大環境分析
波特的五力分析
市場動態和趨勢
- 成長促進因素
- 課題
- 主要趨勢
COVID-19對市場成長趨勢的影響的評估
市場成長及預測
- 市場收益的估計與預測(2020年～2033年)
- 市場規模的估計與預測(2020年～2033年)
競爭儀表板
- 市場集中率
- 企業的市場佔有率分析(金額)(2024年)
- 競爭製圖

第5章全球止血劑市場分析:各類型

重要的知識見解
市場規模與預測(2020年～2033年)
- 局部止血劑
- 其他

第6章全球止血劑市場分析:各製劑

重要的知識見解
市場規模與預測(2020年～2033年)
- 薄板·墊片止血劑
- 海綿止血劑
- 粉末止血劑
- 矩陣·凝膠止血劑
- 其他

第7章全球止血劑市場分析:各用途

重要的知識見解
市場規模與預測(2020年～2033年)
- 整形外科手術
- 一般外科手術
- 神經外科手術
- 心血管手術
- 重組手術
- 婦產科手術
- 其他

第8章全球止血劑市場分析:各終端用戶

重要的知識見解
市場規模與預測(2020年～2033年)
- 醫院
- 門診病人手術中心
- 居家照護
- 其他

第9章全球止血劑市場分析:各流通管道

重要的知識見解
市場規模與預測(2020年～2033年)
- 線上
- 離線

第10章全球止血劑市場分析:各地區

重要的知識見解
市場規模與預測(2020年～2033年)
- 北美
- 歐洲
- 亞太地區
- 中東·非洲
- 南美

第11章北美的止血劑市場分析

重要的知識見解
市場規模與預測(2020年～2033年)
- 各類型
- 各製劑
- 各用途
- 各終端用戶
- 各流通管道
- 各國

第12章歐洲的止血劑市場分析

重要的知識見解
市場規模與預測(2020年～2033年)
- 各類型
- 各製劑
- 各用途
- 各終端用戶
- 各流通管道
- 各國

第13章亞太地區的止血劑市場分析

重要的知識見解
市場規模與預測(2020年～2033年)
- 各類型
- 各製劑
- 各用途
- 各終端用戶
- 各流通管道
- 各國

第14章中東·非洲的止血劑市場分析

重要的知識見解
市場規模與預測(2020年～2033年)
- 各類型
- 各製劑
- 各用途
- 各終端用戶
- 各流通管道
- 各國

第15章南美的止血劑市場分析

重要的知識見解
市場規模與預測(2020年～2033年)
- 各類型
- 各製劑
- 各用途
- 各終端用戶
- 各流通管道
- 各國

第16章企業簡介

B.Braun Melsungen AG
Baxter International Inc.
Becton Dickinson and Co.
Gelita Medical GmbH
Hemostatis LLC
Integra Life Sciences Holding Corp.
Johnson and Johnson
Medtronic PLC
Pfizer Inc.
Stryker Corp.
Teleflex Inc.
其他的著名的企業

簡介目錄

Product Code: AA0724861

The hemostats market is closely tied to the pace of surgical activity worldwide, reflecting the growing demand for effective bleeding control in an expanding range of procedures. In 2024, the market is valued at approximately US$ 2,884.13 million and is forecasted to grow steadily, reaching an estimated valuation of US$ 4,839.68 million by 2033. This growth corresponds to a compound annual growth rate (CAGR) of 5.92% between 2025 and 2033. One of the key drivers behind this expansion is the increasing adoption of minimally invasive surgical techniques, such as laparoscopic and robotic surgeries.

Regionally, North America continues to dominate the hemostats market in terms of procedural consumption, benefiting from a well-established healthcare infrastructure and high surgical volumes. However, the Asia-Pacific region is rapidly gaining ground, propelled by significant investments in government-funded trauma networks and a surge in laparoscopic surgeries, especially in populous countries like China and India. This growth signals a shift in market dynamics as Asia-Pacific emerges as a vital growth engine for hemostatic product manufacturers seeking to capitalize on increasing surgical activities and expanding healthcare access in the region.

Noteworthy Market Developments

The hemostats market is led by several prominent companies, including Johnson & Johnson, Baxter International, Pfizer Inc., B. Braun SE, and Becton, Dickinson and Company (BD). These industry giants boast a strong global footprint and remain deeply committed to advancing their market positions through vigorous research and development efforts, strategic partnerships, and continuous product innovation.

Baxter International exemplifies this innovation-driven approach with its Applied Hemostasis laboratory, staffed by a team of 50 scientists dedicated to developing next-generation hemostatic solutions. In 2023 alone, this lab filed 42 patent families, focusing on advanced materials such as shear-thinning gelatin and lyoprotected thrombin combinations. These innovations aim to improve the efficacy and application versatility of hemostats, addressing the nuanced needs of modern surgical procedures.

Meanwhile, BD has strategically expanded its portfolio through acquisitions, exemplified by its purchase of Tissuemed for $214 million. This acquisition granted BD access to Tissuemed's ultra-thin polyethylene glycol patch technology, enhancing its product breadth and enabling it to offer more specialized and effective hemostatic options to the market. Such moves demonstrate BD's commitment to strengthening its position through targeted investments in innovative products.

Core Growth Drivers

The rapid growth in minimally invasive surgery (MIS) volumes stands out as the most powerful driver fueling expansion in the hemostats market. According to the International Society for Minimally Invasive Surgery, approximately 108 million laparoscopic, robotic, and endoscopic procedures are expected to be performed globally in 2024. This represents an increase of about 11 million cases compared to 2022, highlighting the accelerating adoption of MIS techniques across a wide range of surgical specialties.

Hemostatic agents are now deployed in roughly one out of every three minimally invasive surgeries, translating to nearly 36 million units utilized in 2024 alone. This widespread integration underscores the vital role hemostats play in enabling safe and efficient MIS procedures. The continued expansion of minimally invasive techniques is expected to sustain strong demand for hemostatic products, further driving innovation and growth within the market

Emerging Opportunity Trends

Scientific interest is increasingly shifting toward hybrid collagen-chitosan hemostats, a trend that is significantly reshaping the competitive dynamics within the hemostats market. These hybrid formulations combine the beneficial properties of collagen with the unique features of chitosan, offering enhanced hemostatic performance and improved tissue compatibility. Between January 2023 and March 2024, the European Database on Medical Devices (EUDAMED) recorded 11 new CE Mark approvals for collagen-chitosan composite products, a stark contrast to the mere three approvals granted for oxidized cellulose-based hemostats during the same period.

In the United States, the Food and Drug Administration (FDA) cleared six collagen-chitosan hybrid hemostats within the same timeframe. Notably, half of these products received Breakthrough Device designation, underscoring their innovative nature and clinical promise. These designations were largely based on rapid clot formation benchmarks demonstrated through preclinical testing, where bleeding times were reduced to under 20 seconds in porcine liver models.

Barriers to Optimization

Rising raw-material prices are significantly impacting profitability within the bovine-collagen-based biosurgicals segment, posing a substantial challenge to the hemostats market in 2024. According to data from the U.S. Department of Agriculture, the cost of medical-grade bovine tendon collagen surged to $19.40 per kilogram in April 2024, up sharply from $13.00 per kilogram in 2022. Although the amount of purified collagen used in each absorbable patch averages just 1.9 grams, this increase translates to a material cost of approximately $0.037 per unit.

Baxter's most recent 10-K filing highlights the financial strain caused by these raw material price hikes, reporting a $94 million year-over-year increase in biomaterial expenditures, driven predominantly by rising bovine collagen costs. This surge has compressed gross margins by roughly $6 per device, a notable figure that directly affects profitability. To counterbalance these increased costs, manufacturers have implemented price adjustments at the SKU level, with hospital group purchasing organization (GPO) catalogs reflecting average price hikes of around $9 per unit.

Detailed Market Segmentation

By Type, the topical category occupies a dominant position in the hemostats market, commanding over 85.46% of the total market share. This prominence is largely attributed to the versatility and convenience that topical hemostatic agents offer across a broad spectrum of surgical workflows. Unlike some hemostatic products that require specialized equipment or ancillary hardware, topical agents can be applied directly to the bleeding site with minimal preparation, making them highly compatible with both open surgeries and minimally invasive procedures.

By formulation, matrices and gels dominate the hemostats market in terms of formulation revenue, accounting for 34.26% of the total market share. Their popularity stems from their unique ability to combine the ease of handling typically associated with topical agents with the flexibility and adaptability of liquids. This hybrid quality makes them particularly well-suited for controlling bleeding in complex surgical fields where blood loss often originates from irregular cavities or delicate, friable parenchymal tissue.

Based on application, orthopedic surgery represents a significant segment of the hemostats market, capturing more than 30.26% of the total market share based on application. This prominence is largely due to the nature of orthopedic procedures, which tend to generate some of the heaviest routine blood loss among elective surgical specialties. As a result, orthopedic theaters are among the most intensive users of hemostatic products, relying heavily on these adjuncts to manage bleeding effectively during complex joint, spine, and trauma fixation surgeries.

By End Users, hospitals hold a commanding position in the hemostats market, capturing over 56.20% of the total market share. This dominance is primarily due to their responsibility for managing the highest acuity cases, which require a broad range of surgical consumables, including hemostatic products. Hospitals also exercise significant control over procurement formularies, enabling them to standardize and streamline the acquisition of essential items to meet the demands of complex surgical procedures.

Segment Breakdown

By Type

Topical Hemostats
- Mechanical Hemostats
  - ORC Based
  - Gelatin Based
  - Collagen Based
Polysaccharide Based Topical Hemostats
- Active Hemostats
- Flowable Hemostats
Topical Thrombin Based Topical Hemostats
Others

By Formulation

Sheet and Pad Hemostats
Sponge Hemostats
Powder Hemostats
Matrix and Gel Hemostats
Others

By Application

Orthopedic Surgery
General Surgery
Neurological Surgery
Cardiovascular Surgery
Reconstructive Surgery
Gynecological Surgery
Others

By End User

Hospitals
Ambulatory Surgical Centers
Home Care
Others

By Distribution Channel

Online
Offline
- Direct
- Distributor

By Region

North America
- The U.S.
- Canada
- Mexico
Europe
- Western Europe
  - The UK
  - Germany
  - France
  - Italy
  - Spain
  - Rest of Western Europe
- Eastern Europe
  - Poland
  - Russia
  - Rest of Eastern Europe
Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East & Africa (MEA)
- Saudi Arabia
- South Africa
- UAE
- Rest of MEA
South America
- Argentina
- Brazil
- Rest of South America

Leading Market Participants

B.Braun Melsungen AG
Baxter International Inc.
Becton Dickinson and Co.
Gelita Medical GmbH
Hemostatis LLC
Integra Life Sciences Holding Corp.
Johnson and Johnson
Medtronic PLC
Pfizer Inc.
Stryker Corp.
Teleflex Inc.
Other Prominent Players

Table of Content

Chapter 1. Research Framework

1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

Chapter 2. Research Methodology

2.1. Qualitative Research
- 2.1.1. Primary & Secondary Sources
2.2. Quantitative Research
- 2.2.1. Primary & Secondary Sources
2.3. Breakdown of Primary Research Respondents, By Region
2.4. Assumption for the Study
2.5. Market Size Estimation
2.6. Data Triangulation

Chapter 3. Executive Summary: Global Hemostats Market

Chapter 4. Global Hemostats Market Overview

4.1. Industry Value Chain Analysis
- 4.1.1. Material Provider
- 4.1.2. Manufacturer
- 4.1.3. Distributor
- 4.1.4. End User
4.2. Industry Outlook
- 4.2.1. Topical and Externally Administered Hemostatic Biomaterials from Natural Sources
- 4.2.2. Topical and Externally Administered Hemostatic Biomaterials from Synthetic Sources
4.3. PESTLE Analysis
4.4. Porter's Five Forces Analysis
- 4.4.1. Bargaining Power of Suppliers
- 4.4.2. Bargaining Power of Buyers
- 4.4.3. Threat of Substitutes
- 4.4.4. Threat of New Entrants
- 4.4.5. Degree of Competition
4.5. Market Dynamics and Trends
- 4.5.1. Growth Drivers
- 4.5.2. Challenges
- 4.5.3. Key Trends
4.6. Covid-19 Impact Assessment on Market Growth Trend
4.7. Market Growth and Outlook
- 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2033
- 4.7.2. Market Volume Estimates and Forecast (000' Units), 2020 - 2033
4.8. Competition Dashboard
- 4.8.1. Market Concentration Rate
- 4.8.2. Company Market Share Analysis (Value %), 2024
- 4.8.3. Competitor Mapping

Chapter 5. Global Hemostats Market Analysis, By Type

5.1. Key Insights
5.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
- 5.2.1. Topical Hemostats
  - 5.2.1.1. Mechanical Hemostats
    - 5.2.1.1.1. ORC Based
    - 5.2.1.1.2. Gelatin Based
    - 5.2.1.1.3. Collagen Based
  - 5.2.1.2. Polysaccharide Based Topical Hemostats
    - 5.2.1.2.1. Active Hemostats
    - 5.2.1.2.2. Flowable Hemostats
  - 5.2.1.3. Topical Thrombin Based Topical Hemostats
- 5.2.2. Others

Chapter 6. Global Hemostats Market Analysis, By Formulation

6.1. Key Insights
6.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
- 6.2.1. Sheet and Pad Hemostats
- 6.2.2. Sponge Hemostats
- 6.2.3. Powder Hemostats
- 6.2.4. Matrix and Gel Hemostats
- 6.2.5. Others

Chapter 7. Global Hemostats Market Analysis, By Application

7.1. Key Insights
7.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
- 7.2.1. Orthopedic Surgery
- 7.2.2. General Surgery
- 7.2.3. Neurological Surgery
- 7.2.4. Cardiovascular Surgery
- 7.2.5. Reconstructive Surgery
- 7.2.6. Gynecological Surgery
- 7.2.7. Others

Chapter 8. Global Hemostats Market Analysis, By End User

8.1. Key Insights
8.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
- 8.2.1. Hospitals
- 8.2.2. Ambulatory Surgical Centers
- 8.2.3. Home Care
- 8.2.4. Others

Chapter 9. Global Hemostats Market Analysis, By Distribution Channel

9.1. Key Insights
9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
- 9.2.1. Online
- 9.2.2. Offline
  - 9.2.2.1. Direct
  - 9.2.2.2. Distributor

Chapter 10. Global Hemostats Market Analysis, By Region

10.1. Key Insights
10.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
- 10.2.1. North America
  - 10.2.1.1. The U.S.
  - 10.2.1.2. Canada
  - 10.2.1.3. Mexico
- 10.2.2. Europe
  - 10.2.2.1. Western Europe
    - 10.2.2.1.1. The UK
    - 10.2.2.1.2. Germany
    - 10.2.2.1.3. France
    - 10.2.2.1.4. Italy
    - 10.2.2.1.5. Spain
    - 10.2.2.1.6. Rest of Western Europe
  - 10.2.2.2. Eastern Europe
    - 10.2.2.2.1. Poland
    - 10.2.2.2.2. Russia
    - 10.2.2.2.3. Rest of Eastern Europe
- 10.2.3. Asia Pacific
  - 10.2.3.1. China
  - 10.2.3.2. India
  - 10.2.3.3. Japan
  - 10.2.3.4. South Korea
  - 10.2.3.5. Australia & New Zealand
  - 10.2.3.6. ASEAN
  - 10.2.3.7. Rest of Asia Pacific
- 10.2.4. Middle East & Africa
  - 10.2.4.1. UAE
  - 10.2.4.2. Saudi Arabia
  - 10.2.4.3. South Africa
  - 10.2.4.4. Rest of MEA
- 10.2.5. South America
  - 10.2.5.1. Argentina
  - 10.2.5.2. Brazil
  - 10.2.5.3. Rest of South America

Chapter 11. North America Hemostats Market Analysis

11.1. Key Insights
11.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
- 11.2.1. By Type
- 11.2.2. By Formulation
- 11.2.3. By Application
- 11.2.4. By End User
- 11.2.5. By Distribution Channel
- 11.2.6. By Country

Chapter 12. Europe Hemostats Market Analysis

12.1. Key Insights
12.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
- 12.2.1. By Type
- 12.2.2. By Formulation
- 12.2.3. By Application
- 12.2.4. By End User
- 12.2.5. By Distribution Channel
- 12.2.6. By Country

Chapter 13. Asia Pacific Hemostats Market Analysis

13.1. Key Insights
13.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
- 13.2.1. By Type
- 13.2.2. By Formulation
- 13.2.3. By Application
- 13.2.4. By End User
- 13.2.5. By Distribution Channel
- 13.2.6. By Country

Chapter 14. Middle East and Africa Hemostats Market Analysis

14.1. Key Insights
14.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
- 14.2.1. By Type
- 14.2.2. By Formulation
- 14.2.3. By Application
- 14.2.4. By End User
- 14.2.5. By Distribution Channel
- 14.2.6. By Country

Chapter 15. South America Hemostats Market Analysis

15.1. Key Insights
15.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
- 15.2.1. By Type
- 15.2.2. By Formulation
- 15.2.3. By Application
- 15.2.4. By End User
- 15.2.5. By Distribution Channel
- 15.2.6. By Country